416 related articles for article (PubMed ID: 21795678)
1. Inhibition of matrix metalloproteinase 14 (MMP-14)-mediated cancer cell migration.
Zarrabi K; Dufour A; Li J; Kuscu C; Pulkoski-Gross A; Zhi J; Hu Y; Sampson NS; Zucker S; Cao J
J Biol Chem; 2011 Sep; 286(38):33167-77. PubMed ID: 21795678
[TBL] [Abstract][Full Text] [Related]
2. Role of matrix metalloproteinase-9 dimers in cell migration: design of inhibitory peptides.
Dufour A; Zucker S; Sampson NS; Kuscu C; Cao J
J Biol Chem; 2010 Nov; 285(46):35944-56. PubMed ID: 20837483
[TBL] [Abstract][Full Text] [Related]
3. Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9.
Dufour A; Sampson NS; Li J; Kuscu C; Rizzo RC; Deleon JL; Zhi J; Jaber N; Liu E; Zucker S; Cao J
Cancer Res; 2011 Jul; 71(14):4977-88. PubMed ID: 21646471
[TBL] [Abstract][Full Text] [Related]
4. Role of the hemopexin domain of matrix metalloproteinases in cell migration.
Dufour A; Sampson NS; Zucker S; Cao J
J Cell Physiol; 2008 Dec; 217(3):643-51. PubMed ID: 18636552
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Hemopexin-like Domain of Latent Matrix Metalloproteinase-9 (proMMP-9) with a Small Molecule Inhibitor Prevents the Formation of Focal Adhesion Junctions.
Alford VM; Kamath A; Ren X; Kumar K; Gan Q; Awwa M; Tong M; Seeliger MA; Cao J; Ojima I; Sampson NS
ACS Chem Biol; 2017 Nov; 12(11):2788-2803. PubMed ID: 28945333
[TBL] [Abstract][Full Text] [Related]
6. Distinct roles for the catalytic and hemopexin domains of membrane type 1-matrix metalloproteinase in substrate degradation and cell migration.
Cao J; Kozarekar P; Pavlaki M; Chiarelli C; Bahou WF; Zucker S
J Biol Chem; 2004 Apr; 279(14):14129-39. PubMed ID: 14729674
[TBL] [Abstract][Full Text] [Related]
7. The second dimer interface of MT1-MMP, the transmembrane domain, is essential for ProMMP-2 activation on the cell surface.
Itoh Y; Ito N; Nagase H; Seiki M
J Biol Chem; 2008 May; 283(19):13053-62. PubMed ID: 18337248
[TBL] [Abstract][Full Text] [Related]
8. Simultaneous targeting of CD44 and MMP9 catalytic and hemopexin domains as a therapeutic strategy.
Yosef G; Hayun H; Papo N
Biochem J; 2021 Mar; 478(5):1139-1157. PubMed ID: 33600567
[TBL] [Abstract][Full Text] [Related]
9. A novel CD44-binding peptide from the pro-matrix metalloproteinase-9 hemopexin domain impairs adhesion and migration of chronic lymphocytic leukemia (CLL) cells.
Ugarte-Berzal E; Bailón E; Amigo-Jiménez I; Albar JP; García-Marco JA; García-Pardo A
J Biol Chem; 2014 May; 289(22):15340-9. PubMed ID: 24739387
[TBL] [Abstract][Full Text] [Related]
10. Novel MT1-MMP small-molecule inhibitors based on insights into hemopexin domain function in tumor growth.
Remacle AG; Golubkov VS; Shiryaev SA; Dahl R; Stebbins JL; Chernov AV; Cheltsov AV; Pellecchia M; Strongin AY
Cancer Res; 2012 May; 72(9):2339-49. PubMed ID: 22406620
[TBL] [Abstract][Full Text] [Related]
11. The matrix metalloproteinase 9 (mmp-9) hemopexin domain is a novel gelatin binding domain and acts as an antagonist.
Roeb E; Schleinkofer K; Kernebeck T; Pötsch S; Jansen B; Behrmann I; Matern S; Grötzinger J
J Biol Chem; 2002 Dec; 277(52):50326-32. PubMed ID: 12384502
[TBL] [Abstract][Full Text] [Related]
12. Src-dependent phosphorylation of membrane type I matrix metalloproteinase on cytoplasmic tyrosine 573: role in endothelial and tumor cell migration.
Nyalendo C; Michaud M; Beaulieu E; Roghi C; Murphy G; Gingras D; Béliveau R
J Biol Chem; 2007 May; 282(21):15690-9. PubMed ID: 17389600
[TBL] [Abstract][Full Text] [Related]
13. The dimer interface of the membrane type 1 matrix metalloproteinase hemopexin domain: crystal structure and biological functions.
Tochowicz A; Goettig P; Evans R; Visse R; Shitomi Y; Palmisano R; Ito N; Richter K; Maskos K; Franke D; Svergun D; Nagase H; Bode W; Itoh Y
J Biol Chem; 2011 Mar; 286(9):7587-600. PubMed ID: 21193411
[TBL] [Abstract][Full Text] [Related]
14. MMP-9-hemopexin domain hampers adhesion and migration of colorectal cancer cells.
Burg-Roderfeld M; Roderfeld M; Wagner S; Henkel C; Grötzinger J; Roeb E
Int J Oncol; 2007 Apr; 30(4):985-92. PubMed ID: 17332939
[TBL] [Abstract][Full Text] [Related]
15. The role of a new CD44st in increasing the invasion capability of the human breast cancer cell line MCF-7.
Fang XJ; Jiang H; Zhao XP; Jiang WM
BMC Cancer; 2011 Jul; 11():290. PubMed ID: 21749678
[TBL] [Abstract][Full Text] [Related]
16. Peptide from the C-terminal domain of tissue inhibitor of matrix metalloproteinases-2 (TIMP-2) inhibits membrane activation of matrix metalloproteinase-2 (MMP-2).
Xu X; Mikhailova M; Chen Z; Pal S; Robichaud TK; Lafer EM; Baber S; Steffensen B
Matrix Biol; 2011 Sep; 30(7-8):404-12. PubMed ID: 21839835
[TBL] [Abstract][Full Text] [Related]
17. Rapid expression and activation of MMP-2 and MMP-9 upon exposure of human breast cancer cells (MCF-7) to fibronectin in serum free medium.
Das S; Banerji A; Frei E; Chatterjee A
Life Sci; 2008 Feb; 82(9-10):467-76. PubMed ID: 18243246
[TBL] [Abstract][Full Text] [Related]
18. Epidermal growth factor receptor-mediated regulation of matrix metalloproteinase-2 and matrix metalloproteinase-9 in MCF-7 breast cancer cells.
Majumder A; Ray S; Banerji A
Mol Cell Biochem; 2019 Feb; 452(1-2):111-121. PubMed ID: 30074136
[TBL] [Abstract][Full Text] [Related]
19. The hemopexin domain of matrix metalloproteinase-9 activates cell signaling and promotes migration of schwann cells by binding to low-density lipoprotein receptor-related protein.
Mantuano E; Inoue G; Li X; Takahashi K; Gaultier A; Gonias SL; Campana WM
J Neurosci; 2008 Nov; 28(45):11571-82. PubMed ID: 18987193
[TBL] [Abstract][Full Text] [Related]
20. Enhanced membrane-type 1 matrix metalloproteinase expression by hyaluronan oligosaccharides in breast cancer cells facilitates CD44 cleavage and tumor cell migration.
Kung CI; Chen CY; Yang CC; Lin CY; Chen TH; Wang HS
Oncol Rep; 2012 Nov; 28(5):1808-14. PubMed ID: 22922740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
